Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

28/04/2021

Articles, Publications, Publications Breast

Sibylle Loibl, Frederik Marmé, Miguel Martin, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Mireia Melé Olivé, Karen Gelmon, José García-Sáenz, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Hope S. Rugo, Carsten Denkert, Michael Gnant, Andreas Makris, Maria Koehler, Cynthia Huang-Bartelett, Maria Jose Lechuga Frean, Marco Colleoni, Gustavo Werutsky, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Gunter von Minckwitz

DOI: 10.1200/JCO.20.03639

Full link: https://ascopubs.org/doi/full/10.1200/JCO.20.03639

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Send us a message

Cura Project

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Related Posts

TP008/#1422 Epidemiological landscape of cervical cancer in Latin America (EVITA LATAM) – LACOG 0820

Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215)

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

Epidemiological characteristics and survival of patients with diffuse glioma in Brazil: preliminary results of a multicentric retrospective study – LACOG 0619